TABLE 2.
Genotypic characterization of the NS3 protease from GT-1b and GT-1a replicons after telaprevir treatment
| Replicon (no. of expts)a | Residue(s) at position(s) with substitution(s) in NS3 proteaseb on telaprevir treatment day:
|
|||||
|---|---|---|---|---|---|---|
| 3 | 6 | 9 | 13 | 16 | 21 | |
| GT-1b (4) | A156A/S | A156A/S/T | A156A/S/T | A156A/S/T/V | A156A/S/T/V | A156A/S/T/V |
| GT-1a (2) | R155R/K | R155R/K, A156A/T | T54T/A, R155R/K, | T54T/A, R155R/K, A156A/T | R155R/K, A156A/T | R155R/K, A156A/T |
a
Stable GT-1b and GT-1a replicon cell lines were treated with 15 times the EC50 of telaprevir.
b
Results were obtained from direct sequencing of PCR products representing the major population. Only amino acid substitutions known to confer resistance and/or substitutions identified consistently in the independent experiments and not observed in untreated controls are reported. Data were derived from at least two independent cell culture selection experiments.